PMID: 8607228Feb 1, 1996Paper

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

Urology
A L HillmanR J Padley

Abstract

To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers and 141 community-based satellite centers. Information about the use of health care resources and non-disease-specific functional status measures was collected by a standardized telephone interview of patients at baseline and every month thereafter for 12 months. Other information, such as American Urologic Association (AUA) disease-specific functional status scores, was obtained from the patient study records. Patients had a mean age of 65.7 years (range, 46 to 94), with a clinical diagnosis of BPH. At baseline men had at least moderate BPH symptoms by AUA Symptom score (13 or more) and Bother Score (8 or more). On entry, patients at regional sites had peak urinary flow rates 15 mL/s or less and total voided urine volumes 150 mL or greater. A total of 1053 patients were randomized to terazosin and 1031 to placebo treatment. Primary outcome measures included p...Continue Reading

References

Jan 1, 1990·The Prostate. Supplement·M J Barry
May 27, 1988·JAMA : the Journal of the American Medical Association·M J BarryJ W Wennberg
May 27, 1988·JAMA : the Journal of the American Medical Association·F J FowlerD Hanley
Dec 1, 1981·British Journal of Urology·A J BallP H Abrams
Jan 12, 1995·The New England Journal of Medicine·J E Oesterling
Jan 1, 1993·The Prostate·K A WeisG Oster
Apr 1, 1994·Medical Care·D A RevickiG E Simon

❮ Previous
Next ❯

Citations

Feb 23, 1999·The Urologic Clinics of North America·H L Holtgrewe
Nov 1, 1996·Clinical Therapeutics·M A Kortt, J L Bootman
Mar 11, 2005·The Journal of Urology·Christopher S Saigal, Geoffrey Joyce
Sep 30, 2000·PharmacoEconomics·P A De SmetM J Nuijten
May 26, 2010·Clinics in Geriatric Medicine·David R Paolone
Jun 13, 2003·Journal of Occupational and Environmental Medicine·Wayne N BurtonAlbert I Wertheimer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.